PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its ...

PTC Therapeutics, Inc.’s PTCT share price has surged by 6.72%, which has investors questioning if this is right time to sell.

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Learn more about whether Neurocrine Biosciences, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ ...

Detailed price information for Nanobiotix S.A. ADR (NBTX-Q) from The Globe and Mail including charting and trades.

WARREN, N.J., March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the European Commission (EC) has adopted the opinion of the Committee for Medicinal ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PTC Therapeutics (PTCT – Research Report) ...

William Blair analyst Sami Corwin maintained a Hold rating on Applied Therapeutics (APLT – Research Report) today. The company’s shares closed ...

WARREN, N.J., March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 24, 2025, the company approved non-statutory stock options to purchase an aggregate ...

Two dose levels of a single-administration gene therapy were well-tolerated and led to functional improvements in ambulatory ...

March 28 (Reuters) - PTC Therapeutics (PTCT.O), opens new tab said on Friday its inherited progressive muscle-wasting disorder drug will no longer be available for sale in the EU as the European ...

(RTTNews) - PTC Therapeutics, Inc. (PTCT) announced that the European Commission has adopted the opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency to ...